Amylin data doesn't impress Wall Street

It's good data, but is it good enough? Amylin Pharmaceuticals announced that its once-a-week version of the diabetes drug Byetta works better than the twice-a-day version now on the market. It was welcome news for Amylin and its partners Eli Lilly and Alkermes. And potentially for diabetes patients, because keeping the drug at a steady level in the body could be better at preventing complications from blood sugar fluctuations. (Caveat: The FDA warned last month that some Byetta patients developed acute pancreatitis.)

But some stock analysts were disappointed that the difference in efficacy of the two dosing schemes wasn't more dramatic. And others bemoaned the fact that Amylin doesn't intend to ask the FDA to approve the new-and-improved Byetta until 2009. Amylin stock fell 3.8 percent to $46.52.

- see the release from Amylin
- read the San Diego Union-Tribune report
- check out more on the financial angles from the Motley Fool

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.